Jung Won Shin

Jung Won Shin

Senior Editor

Seoul, South Korea

Jung Won focuses on coverage of all aspects of news in the Korean pharma and biotech industry as well as for regulatory matters. She covers major pharma and biotech conferences in Korea as well as interviewing key opinion leaders. She also handles a regular Korean language podcast on Scrip/Pink Sheet stories. She has worked previously for Dow Jones Newswires, covering various industry sectors and the economy.

Latest from Jung Won Shin

Asia Deal Watch: Daiichi Sankyo Teams With Nosis On Extrahepatic RNA Therapies

Plus deals involving Hyundai/Pharma/Avelos, Yuhan/Boehringer Ingelheim, SciClone/Eisai, Viatris/Nxera/Idorsia, Nxera/Holling and Takeda/BridGene.

Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band

The latest activity in the South Korean biotech sector includes IPOs by Orum and Dongkook Life, as well as progress with ADCs at multiple firms.

Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary

Plus deals involving Pfizer/Mylan, Radiance/CSPC, Polymed/Photys, Kyorin/Cyrano, Zydus/Synthon, Ellipses/Genome & Co., OliX/Lilly, AdvanCell/Lilly and more.

Korea Q4 Roundup: Overseas Sales, M&A Provide Growth Amid General Weakness

Several major South Korean pharma firms benefited from solid sales of new drugs, and in some cases M&A deals, outside the country, although overall growth was generally weak. Meanwhile, a long-running leadership dispute at Hanmi has been resolved.

Korea ‘Guide’ Program To Speed Select Innovative Products To Market

In an ongoing effort to accelerate the commercialization of select innovative drugs and medical devices, Korea’s MFDS is launching a new program for certain products that will receive regular regulatory consultations until they reach the approval stage.

Bridge Biotherapeutics Confident In IPF Contender As It Seeks Global Partner

The CEO of Korean biotech Bridge Biotherapeutics shares progress and strategy for its lead candidate for IPF, along with thoughts on what Trump and the ongoing Korean political crisis might mean for the industry.